Back
22
Day Range
$110.03
$115.24
52-Week Range
$96.43
$160.27
Volume
1,074,492
50D / 200D Avg
$127.46
/
$129.95
Prev Close
$112.02
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (627 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 24.8 | 0.3 |
| P/B | 4.8 | 2.9 |
| ROE % | 20.6 | 3.7 |
| Net Margin % | 18.8 | 3.8 |
| Rev Growth 5Y % | 2.4 | 10.0 |
| D/E | 0.5 | 0.2 |
Analyst Price Target
Hold
$165.00
+44.5%
Low: $130.00
High: $180.00
Forward P/E
18.8
Forward EPS
$5.97
EPS Growth (est.)
+0.0%
Est. Revenue
7.4 B
Earnings Estimates
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| FY2030 |
$8.58
$8.47 – $8.69
|
9.3 B | 1 |
| FY2029 |
$8.04
$7.93 – $8.14
|
8.8 B | 1 |
| FY2028 |
$7.29
$6.75 – $7.71
|
8.4 B | 5 |
Key Takeaways
Revenue grew 2.40% annually over 5 years — modest growth
ROE of 20.62% indicates high profitability
Net margin of 18.75% shows strong profitability
Debt/Equity of 0.50 — conservative balance sheet
Generating 1.15B in free cash flow
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 4.33%
Growth
Revenue Growth (5Y)
2.40%
Revenue (1Y)6.73%
Earnings (1Y)1.09%
FCF Growth (3Y)-11.59%
Quality
Return on Equity
20.62%
ROIC10.99%
Net Margin18.75%
Op. Margin21.29%
Safety
Debt / Equity
0.50
Current Ratio1.96
Interest Coverage13.21
Valuation
P/E Ratio
24.79
P/B Ratio4.79
EV/EBITDA22.90
Dividend Yield0.01%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 6.73% | Revenue Growth (3Y) | 0.84% |
| Earnings Growth (1Y) | 1.09% | Earnings Growth (3Y) | 2.51% |
| Revenue Growth (5Y) | 2.40% | Earnings Growth (5Y) | 1.87% |
| Profitability | |||
| Revenue (TTM) | 6.95B | Net Income (TTM) | 1.30B |
| ROE | 20.62% | ROA | 10.24% |
| Gross Margin | 52.43% | Operating Margin | 21.29% |
| Net Margin | 18.75% | Free Cash Flow (TTM) | 1.15B |
| ROIC | 10.99% | FCF Growth (3Y) | -11.59% |
| Safety | |||
| Debt / Equity | 0.50 | Current Ratio | 1.96 |
| Interest Coverage | 13.21 | Dividend Yield | 0.01% |
| Valuation | |||
| P/E Ratio | 24.79 | P/B Ratio | 4.79 |
| P/S Ratio | 4.65 | PEG Ratio | 9.41 |
| EV/EBITDA | 22.90 | Dividend Yield | 0.01% |
| Market Cap | 32.30B | Enterprise Value | 33.87B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 6.95B | 6.51B | 6.83B | 6.85B | 6.32B |
| Net Income | 1.30B | 1.29B | 1.24B | 1.25B | 1.21B |
| EPS (Diluted) | 4.57 | 4.43 | 4.19 | 4.18 | 3.94 |
| Gross Profit | 3.64B | 3.54B | 3.47B | 3.72B | 3.41B |
| Operating Income | 1.48B | 1.49B | 1.35B | 1.62B | 1.35B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 12.73B | 11.85B | 10.76B | 10.53B | 10.71B |
| Total Liabilities | 5.99B | 5.95B | 4.92B | 5.23B | 5.32B |
| Shareholders' Equity | 6.74B | 5.90B | 5.85B | 5.31B | 5.39B |
| Total Debt | 3.35B | 3.57B | 2.74B | 2.77B | 2.73B |
| Cash & Equivalents | 1.79B | 1.33B | 1.59B | 1.05B | 1.48B |
| Current Assets | 4.59B | 3.96B | 4.19B | 3.78B | 3.80B |
| Current Liabilities | 2.35B | 1.90B | 1.60B | 1.86B | 1.71B |
Strategy Scores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#959 of 1052
Recent Activity
Entered
Cash Flow Compounder
Mar 24, 2026